Drug Search Results
More Filters [+]

Sarpogrelate

Alternative Names: sarpogrelate, mci-9042, anplag
Latest Update: 2024-07-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT2A Antagonist,GPIIb/IIIa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Korea

Approved Indications: None

Known Adverse Events: None

Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sarpogrelate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Angina Pectoris, Variant|Peripheral Arterial Disease|Thrombophilia|Myocardial Ischemia|Coronary Artery Disease|Peripheral Vascular Diseases|Intermittent Claudication|Arterial Occlusive Diseases|Kidney Diseases|Kidney Failure, Chronic|Diabetic Nephropathy

Phase 3: Ischemic Stroke|Peripheral Vascular Diseases|Peripheral Arterial Disease|Coronary Artery Disease|Kidney Failure, Chronic|Myocardial Ischemia

Phase 1: Healthy Volunteers|Peripheral Arterial Disease|Malnutrition|Hypertension|Chronic Pain

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SEUMC 2023-10-009

N/A

Not yet recruiting

Atherosclerosis|Intermittent Claudication|Stroke

2028-06-30

YMC047

P4

Recruiting

Peripheral Arterial Disease|Coronary Artery Disease|Peripheral Vascular Diseases|Myocardial Ischemia

2024-02-28

YMC044

P4

Completed

Intermittent Claudication|Arterial Occlusive Diseases

2023-03-09

DWAP_P401

N/A

Completed

Arterial Occlusive Diseases

2022-01-20

Recent News Events